TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35105522

Group type: EXPERIMENTAL
Intervention: Heartech left ventricular partitioning device (LVPD) therapy
Number of subjects: 16
Study: 35105572

Group type: EXPERIMENTAL
Intervention: Hypo-METRICS app
Number of subjects: 0
Study: 35105576

Group type: EXPERIMENTAL
Intervention: Online volunteer-led group exercise
Number of subjects: 30
Study: 35105587

Group type: EXPERIMENTAL
Intervention: ACL repair and InternalBrace augmentation
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: ACL reconstruction using hamstring autografts
Number of subjects: 90

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 90
Study: 35105633

Group type: EXPERIMENTAL
Intervention: Celecoxib as an adjunct to treatment-as-usual
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo as an adjunct to treatment-as-usual
Number of subjects: 0
Study: 35105642

Group type: EXPERIMENTAL
Intervention: Capillary blood sample antibody POCT targeting IgM and IgG against the receptor-binding domain of SARS-CoV-2
Number of subjects: 9
Study: 35105647

Group type: EXPERIMENTAL
Intervention: Endoscopic third ventriculostomy (ETV)
Number of subjects: 0
Study: 35105709

Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 306
Study: 35105722

Group type: EXPERIMENTAL
Intervention: Intravenous 120 mg belimumab
Number of subjects: 334

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 334
Study: 35105939

Group type: EXPERIMENTAL
Intervention: Targeting sphingosine-1-phosphate (S1P) in LAR tumors
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: N-acetyl-aspartyl-glutamate as a therapeutic target
Number of subjects: 330
Study: 35105942

Group type: EXPERIMENTAL
Intervention: Fasted state
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Postprandial state
Number of subjects: 30
Study: 35106698

Group type: EXPERIMENTAL
Intervention: Levodopa/carbidopa treatment in 5 patients with dystonia
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Brain MRI studies
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Genetic analysis
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Immunoblotting for PEX16 protein
Number of subjects: 7
Study: 35106709

Group type: EXPERIMENTAL
Intervention: Change in lean body mass index (LBMI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Change in fat mass
Number of subjects: 0
Study: 35106743

Group type: EXPERIMENTAL
Intervention: Salivary cortisol levels
Number of subjects: 112

Group type: COMPARATOR
Intervention: Salivary alpha-amylase levels
Number of subjects: 112
Study: 35106962

Group type: EXPERIMENTAL
Intervention: Isatuximab monotherapy
Number of subjects: 14
Study: 35107547

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation
Number of subjects: 77

Group type: COMPARATOR
Intervention: Conventional oxygen therapy
Number of subjects: 77
Study: 35107642

Group type: EXPERIMENTAL
Intervention: Holmium-166 radioembolization
Number of subjects: 31
Study: 35107750

Group type: EXPERIMENTAL
Intervention: Droxidopa (100-600 mg, 3 times daily)
Number of subjects: 114
Study: 35107821

Group type: EXPERIMENTAL
Intervention: Adherence to social distancing measures
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Higher occupational risk groups
Number of subjects: 1008

Group type: COMPARATOR
Intervention: Overall population
Number of subjects: 1008

Group type: COMPARATOR
Intervention: RT-PCR testing
Number of subjects: 1008

Group type: COMPARATOR
Intervention: IgG serologic testing
Number of subjects: 1008

Group type: COMPARATOR
Intervention: Both RT-PCR and IgG testing
Number of subjects: 1008
Study: 35107848

Group type: EXPERIMENTAL
Intervention: Inactivated COVID-19 vaccine
Number of subjects: 362
Study: 35108379

Group type: EXPERIMENTAL
Intervention: DMARDs (Disease-Modifying Anti-Rheumatic Drugs)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: SSc patients
Number of subjects: 71

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 71
Study: 35108395

Group type: EXPERIMENTAL
Intervention: ADPKD patients with a previous diagnosis of IAs
Number of subjects: 2449

Group type: EXPERIMENTAL
Intervention: Female sex, hypertension <35 years, smoking, and PKD1 genotype
Number of subjects: 2449

Group type: EXPERIMENTAL
Intervention: Postmenopausal women
Number of subjects: 2449
Study: 35109669

Group type: EXPERIMENTAL
Intervention: CKmito overexpression in mice
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Chronic isoproterenol stimulation in CKmito-overexpressing mice
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Limited CK capacity due to creatine substrate depletion in CKmito-overexpressing mice
Number of subjects: 27

Group type: COMPARATOR
Intervention: Measurement of cardiac energetics and left ventricular remodeling
Number of subjects: 27
Study: 35109696

Group type: EXPERIMENTAL
Intervention: Robot-Assisted Radical Cystectomy with Intracorporeal Urinary Diversion
Number of subjects: 0
Study: 35109806

Group type: EXPERIMENTAL
Intervention: Thermal ablation
Number of subjects: 399
Study: 35109819

Group type: EXPERIMENTAL
Intervention: Meeting the MVPA recommendation (≥150 min/week)
Number of subjects: 2338

Group type: EXPERIMENTAL
Intervention: Meeting the ST recommendation (≤8 h/day)
Number of subjects: 2338

Group type: EXPERIMENTAL
Intervention: Meeting the sleep duration recommendation (7-9 h/day)
Number of subjects: 2338

Group type: EXPERIMENTAL
Intervention: Meeting all three 24-hour movement guideline recommendations
Number of subjects: 2338

Group type: COMPARATOR
Intervention: Being a woman
Number of subjects: 2338

Group type: COMPARATOR
Intervention: Having a middle education level
Number of subjects: 2338

Group type: COMPARATOR
Intervention: Having a high education level
Number of subjects: 2338

Group type: COMPARATOR
Intervention: Being married
Number of subjects: 2338

Group type: COMPARATOR
Intervention: Aged 50-64 years
Number of subjects: 2338
Study: 35109900

Group type: EXPERIMENTAL
Intervention: Active feedback with in situ inter-professional simulation-training programme
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Passive feedback with wide dissemination of Morbidity and Mortality conference results
Number of subjects: 15

Group type: COMPARATOR
Intervention: Standard MMC (control arm)
Number of subjects: 15
Study: 35109911

Group type: EXPERIMENTAL
Intervention: Plasma Aβ seeding activity in AD patients
Number of subjects: 218

Group type: COMPARATOR
Intervention: Plasma Aβ seeding activity in NADD patients
Number of subjects: 218

Group type: COMPARATOR
Intervention: Plasma Aβ seeding activity in NC subjects
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Plasma Aβ seeding activity
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Correlation with cognitive performance
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Correlation with conventional biomarkers
Number of subjects: 218
Study: 35109924

Group type: EXPERIMENTAL
Intervention: Nucleus accumbens deep brain stimulation (NAcc-DBS)
Number of subjects: 6
Study: 35110167

Group type: EXPERIMENTAL
Intervention: Group art therapy using clay (6 sessions of 1.5 hours each)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (face-to-face interviews only)
Number of subjects: 60
Study: 35110321

Group type: EXPERIMENTAL
Intervention: Cardiac CT angiography (CCTA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Follow-up CCTA
Number of subjects: 60
Study: 35110356

Group type: EXPERIMENTAL
Intervention: PSMA×CD3 bispecific antibody (bsAb)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Platelet activation
Number of subjects: 0
Study: 35110384

Group type: EXPERIMENTAL
Intervention: Asian group
Number of subjects: 1412

Group type: COMPARATOR
Intervention: Non-Asian group
Number of subjects: 1412
Study: 35110417

Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg daily with binimetinib 45 mg twice daily
Number of subjects: 23
Study: 35110690

Group type: EXPERIMENTAL
Intervention: Familial haploidentical stem cell transplant (haploidentical SCT)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Parent ratings of child's global health-related quality of life (HRQoL)
Number of subjects: 19
Study: 35111295

Group type: EXPERIMENTAL
Intervention: Switching to aripiprazole with 2-week dual administration and tapering off original agents (fast: n=38, slow: n=41)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Baseline chlorpromazine equivalent dose in ARE+ group (405.8 ± 225.8 mg)
Number of subjects: 79
Study: 35111398

Group type: EXPERIMENTAL
Intervention: Hyperglycemic infusion
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic euglycemic clamps
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pancreatic clamp conditions with hyperglycemia
Number of subjects: 30
Study: 35111828

Group type: EXPERIMENTAL
Intervention: Medical treatment with LVEF ≤55%
Number of subjects: 1211

Group type: EXPERIMENTAL
Intervention: Early surgical correction of moderate AR for patients with LVEF 35-55%
Number of subjects: 1211

Group type: EXPERIMENTAL
Intervention: LVEF as a prognostic factor
Number of subjects: 1211
Study: 35112104

Group type: EXPERIMENTAL
Intervention: Pharmaceutical venous thromboembolism (pVTE) prophylaxis
Number of subjects: 2006

Group type: COMPARATOR
Intervention: No pVTE prophylaxis (control group)
Number of subjects: 2006
Study: 35112128

Group type: EXPERIMENTAL
Intervention: Exposure to Gun Violence (GV)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Parental beliefs about guns and gun safety
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Support for firearm injury prevention (FIP) counseling
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Agreement on gun safety measures
Number of subjects: 225
Study: 35112299

Group type: EXPERIMENTAL
Intervention: Dienogest therapy
Number of subjects: 887
Study: 35112303

Group type: EXPERIMENTAL
Intervention: Intraoperative phlebotomy
Number of subjects: 679
Study: 35112306

Group type: EXPERIMENTAL
Intervention: Kidney failure-related encounters
Number of subjects: 237734

Group type: EXPERIMENTAL
Intervention: Cardiovascular-related encounters
Number of subjects: 237734

Group type: EXPERIMENTAL
Intervention: Infection-related encounters
Number of subjects: 237734

Group type: EXPERIMENTAL
Intervention: Medicaid-covered encounters
Number of subjects: 237734

Group type: EXPERIMENTAL
Intervention: Overall encounters
Number of subjects: 237734
Study: 35112307

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab in a treat-and-extend (TAE) regimen
Number of subjects: 75
Study: 35112343

Group type: EXPERIMENTAL
Intervention: Bardet-Biedl syndrome individuals with kidney failure (KF)
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Bardet-Biedl syndrome individuals with recessive causal variants
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Bardet-Biedl syndrome individuals with truncating variants
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Bardet-Biedl syndrome individuals with genes not belonging to the BBSome or chaperonin-like genes
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Bardet-Biedl syndrome individuals with diverse uropathies
Number of subjects: 607
Study: 35112382

Group type: EXPERIMENTAL
Intervention: Fuzuloparib (150 mg single dose)
Number of subjects: 0
Study: 35112882

Group type: EXPERIMENTAL
Intervention: Postrandomization cardiovascular events (myocardial infarction, stroke, hospitalization for unstable angina or heart failure)
Number of subjects: 18144

Group type: COMPARATOR
Intervention: No postrandomization cardiovascular events
Number of subjects: 18144

Group type: EXPERIMENTAL
Intervention: Postrandomization myocardial infarction
Number of subjects: 18144

Group type: EXPERIMENTAL
Intervention: Postrandomization heart failure
Number of subjects: 18144
Study: 35112886

Group type: EXPERIMENTAL
Intervention: ECG LVH defined by Cornell criteria
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: ECG LVH defined by Sokolow-Lyon criteria
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: ECG LVH defined by Romhilt-Estes criteria
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: Patients with ECG LVH
Number of subjects: 596
Study: 35112928

Group type: EXPERIMENTAL
Intervention: Pcrit measurement during drug-induced sleep endoscopy (DISE)
Number of subjects: 13
Study: 35112976

Group type: EXPERIMENTAL
Intervention: suPAR concentrations
Number of subjects: 968

Group type: EXPERIMENTAL
Intervention: suPAR as a predictor
Number of subjects: 968

Group type: EXPERIMENTAL
Intervention: Diagnostic utility of suPAR
Number of subjects: 968
Study: 35113020

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Smartphone App
Number of subjects: 29
Study: 35113028

Group type: EXPERIMENTAL
Intervention: VR food cues
Number of subjects: 175

Group type: COMPARATOR
Intervention: RL food cues
Number of subjects: 175
Study: 35113285

Group type: EXPERIMENTAL
Intervention: Sym013 at 4 mg/kg once-weekly (changed to biweekly due to adverse events)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Sym013 at 15 mg/kg biweekly (Q2W)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Sym013 (various doses)
Number of subjects: 32
Study: 35113363

Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) treatment for rheumatoid arthritis
Number of subjects: 824
Study: 35113812

Group type: EXPERIMENTAL
Intervention: Fresolimumab (TGF-β neutralizing antibody)
Number of subjects: 8
Study: 35113830

Group type: EXPERIMENTAL
Intervention: Contour device
Number of subjects: 34
Study: 35113860

Group type: EXPERIMENTAL
Intervention: Behavioral Activation for Health and Depression (BA-HD)
Number of subjects: 8
Study: 35113934

Group type: EXPERIMENTAL
Intervention: Interferon-γ (IFN-γ) administration
Number of subjects: 0
Study: 35114059

Group type: EXPERIMENTAL
Intervention: Percutaneous mechanical thrombectomy
Number of subjects: 250
Study: 35114169

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg intravenously every 3 weeks for 2 years or until disease progression
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 112
Study: 35114404

Group type: EXPERIMENTAL
Intervention: Drugs suspected of inducing APS (14 drugs identified)
Number of subjects: 790

Group type: EXPERIMENTAL
Intervention: Bayesian disproportionality indicator (information component, IC)
Number of subjects: 790
Study: 35114739

Group type: EXPERIMENTAL
Intervention: Social Functioning
Number of subjects: 0
Study: 35114807

Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 64
Study: 35114814

Group type: EXPERIMENTAL
Intervention: 1-month dual antiplatelet therapy after Synergy bioresorbable-polymer everolimus-eluting stent implantation
Number of subjects: 0
Study: 35115084

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 4744

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4744
Study: 35115085

Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan (Sac/Val)
Number of subjects: 367
Study: 35115167

Group type: EXPERIMENTAL
Intervention: Whole exome sequencing (WES)
Number of subjects: 36
Study: 35115195

Group type: EXPERIMENTAL
Intervention: AKS-452 22.5 µg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: AKS-452 45 µg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: AKS-452 90 µg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: AKS-452 (all doses)
Number of subjects: 60
Study: 35115306

Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy (radiotherapy with or without chemotherapy)
Number of subjects: 32
Study: 35115349

Group type: EXPERIMENTAL
Intervention: Recruitment success factors
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Recruitment rates
Number of subjects: 10
Study: 35115444

Group type: EXPERIMENTAL
Intervention: Hysteroscopic sterilization
Number of subjects: 29971
Study: 35115610

Group type: EXPERIMENTAL
Intervention: Repeated Breathhold (RBH)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Free Breathing (FTBH)
Number of subjects: 20
Study: 35115707

Group type: EXPERIMENTAL
Intervention: H2 vaccination with modified hemagglutinin (HA) containing Phe45 residue
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard H2 vaccination without modification
Number of subjects: 0
Study: 35116390

Group type: EXPERIMENTAL
Intervention: Single-incision plus one port laparoscopic surgery (SILS plus one) with ERAS management
Number of subjects: 120
Study: 35118382

Group type: EXPERIMENTAL
Intervention: Gliadel 7.7 mg implant (up to 8 wafers, 61.6 mg of carmustine)
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Gliadel 7.7 mg implant
Number of subjects: 506
Study: 35118814

Group type: EXPERIMENTAL
Intervention: COVID cohort
Number of subjects: 81

Group type: COMPARATOR
Intervention: Pre-COVID cohort
Number of subjects: 81
Study: 35118821

Group type: EXPERIMENTAL
Intervention: Enzalutamide 160 mg once daily from day 8 to day 71
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (matching enzalutamide) on day 1
Number of subjects: 0
Study: 35118823

Group type: EXPERIMENTAL
Intervention: mCMP-registry (investigator-initiated prospective registry)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Data-driven approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypothesis-driven approach
Number of subjects: 0
Study: 35118915

Group type: EXPERIMENTAL
Intervention: Metatranscriptomic sequencing of bronchial biopsies
Number of subjects: 0
Study: 35119037

Group type: EXPERIMENTAL
Intervention: Triptorelin 3.75 mg once every 28 days for up to 24 weeks after conservative surgery for DIE
Number of subjects: 384
Study: 35119351

Group type: EXPERIMENTAL
Intervention: CF-PDI/T (Craniofacial Pain and Disability Inventory - Turkish version)
Number of subjects: 0
Study: 35119374

Group type: EXPERIMENTAL
Intervention: Digital lifestyle intervention (2-year duration, personalized health coaching program targeting modifiable risk factors for AD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Health education control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Digital lifestyle intervention
Number of subjects: 0
Study: 35119377

Group type: EXPERIMENTAL
Intervention: Videoconference groups
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: In-person groups
Number of subjects: 200

Group type: COMPARATOR
Intervention: Web-based videos
Number of subjects: 200
Study: 35119530

Group type: EXPERIMENTAL
Intervention: Neo-adjuvant chemotherapy (NAC) for early TN ILC
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Neo-adjuvant chemotherapy (NAC) for early HER2+ ILC
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Early TN ILC
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Early HER2+ ILC
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Advanced TN ILC
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Advanced HER2+ ILC
Number of subjects: 86
Study: 35120043

Group type: EXPERIMENTAL
Intervention: Clusters of double triggering and ineffective inspiratory efforts
Number of subjects: 180
Study: 35120446

Group type: EXPERIMENTAL
Intervention: First-line anti-TNF therapy for UC
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: First-line anti-TNF therapy for CD
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: First-line anti-TNF therapy for both UC and CD
Number of subjects: 287
Study: 35120657

Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 0
Study: 35120668

Group type: EXPERIMENTAL
Intervention: Lifestyle program targeting weight management during menopause
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Focus group discussions
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Association with other women affected by menopause
Number of subjects: 27
Study: 35120836

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35120987

Group type: EXPERIMENTAL
Intervention: Treatment of primary ciliary dyskinesia pulmonary exacerbations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reducing inflammation
Number of subjects: 0
Study: 35121604

Group type: EXPERIMENTAL
Intervention: Implementation of a multifaceted CRRT quality assurance and improvement programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pre-implementation group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Post-implementation group
Number of subjects: 0
Study: 35121676

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I) delivered via telehealth, four-session protocol, details on dosage and duration not specified.
Number of subjects: 0
Study: 35121719

Group type: EXPERIMENTAL
Intervention: Biofinity single vision contact lens (SVCL)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Biofinity Multifocal D +2.50 add
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: NaturalVue Multifocal
Number of subjects: 25
Study: 35121763

Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance analysis (BIA) using Omron HBF-306C
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dual X-ray absorptiometry (DXA)
Number of subjects: 0
Study: 35121899

Group type: EXPERIMENTAL
Intervention: BNT162b2 or AZD1222 vaccines (two doses, administered 12 weeks apart)
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: BNT162b2 or AZD1222 vaccines
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: Previous SARS-CoV-2 infection
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: Anti-CD20 treatment
Number of subjects: 585
Study: 35121950

Group type: EXPERIMENTAL
Intervention: ctDNA analysis
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: ctDNA clearance during treatment
Number of subjects: 94
Study: 35122060

Group type: EXPERIMENTAL
Intervention: Combination of radiation, ipilimumab, and nivolumab
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Radiation (per-protocol analysis)
Number of subjects: 65
Study: 35122234

Group type: EXPERIMENTAL
Intervention: E-learning module for neuromuscular monitoring
Number of subjects: 6525
Study: 35122371

Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy (EVT) with intravenous thrombolysis (IVT)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Intravenous thrombolysis (IVT) alone
Number of subjects: 272

Group type: COMPARATOR
Intervention: IVT (in a second PS-matched analysis)
Number of subjects: 272
Study: 35122700

Group type: EXPERIMENTAL
Intervention: LY2780301 plus weekly paclitaxel
Number of subjects: 51
Study: 35122887

Group type: EXPERIMENTAL
Intervention: Sanibit electronic HH system
Number of subjects: 27
Study: 35123074

Group type: COMPARATOR
Intervention: Guideline-based care (V1 to V2)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Biomarker-informed care (V2 to V3)
Number of subjects: 21
Study: 35123422

Group type: EXPERIMENTAL
Intervention: Longitudinal flow cytometry-based monitoring of minimal residual disease (flow-MRD)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Biochemical assessments (serum free light chain and M-component)
Number of subjects: 20
Study: 35123437

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 vaccination
Number of subjects: 12000

Group type: COMPARATOR
Intervention: Control group of non-vaccinated patients
Number of subjects: 12000